A new article study published in Expert Review of Clinical Immunology discussed that allergic rhinitis (AR) is a common chronic condition affecting both, children and adults. House dust mite (HDM) is one of the most frequent sources of allergens. In patients where allergen avoidance and symptom-relieving pharmacotherapy do not provide adequate disease control, specific allergen immunotherapy (AIT) is indicated. While subcutaneous injection (SCIT) is considered as a time-consuming and invasive treatment regimen, sublingual allergy immunotherapy (SLIT) appears as the more convenient treatment strategy. This article reported that clinical trials behind the development of the standardized quality (SQ) HDM-SLIT have demonstrated that the tablet provides safe, well-tolerated and robust efficacy in the treatment of HDM-induced allergic rhinoconjunctivitis. In addition, studies show that the SQ HDM SLIT-tablet is a cost-effective treatment option compared to SCIT.